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We were deeply honoured that so many reputable scholars read our article and took the effort to write no less than eight thoughtful and interesting 
commentaries.1-8 Writing the original paper was sometimes a 
struggle, because it was an unconventional paper. However, 
we felt a strong urge to make these assessments – that are often 
confidential and not publicly available – public, and share 
our experiences to advance this important and timely field 
of research. We hoped that sharing our experiences would 
fuel the discussions on early health economic modeling, but 
these eight commentaries exceeded our expectations. We are 
grateful to the many suggestions for further improvement that 
were provided, and generally agree with all of them. Many 
interesting topics were raised that need further attention, 
such as the use of early health economic modeling within the 
context of early dialogues with payers and health technology 
assessment bodies at early stages of product development,1,2 the 
use of real world evidence,3,8 the complexity of interventions 
and systems,6 and model quality.7 
In this response, we take the opportunity to further discuss 
three topics that were mentioned by multiple scholars: the 
dealing with uncertainty in early health economic modeling, 
the notion of value and the iterative nature of health economic 
modelling.
Dealing With Uncertainty
In the assessments, we did not address parameter uncertainty 
by means of probabilistic sensitivity analysis (PSA), despite 
this being recommended as best practice in health economic 
modeling.9 As explained in the discussion section, we agree 
that it is informative to use PSA for uncertainties that are 
due to imprecision. If there is some (pilot) evidence on the 
effectiveness of the innovative technology, PSA is indeed 
recommended. A major advantage is that it allows for a 
value of information analysis, as suggested by Drummond.1 
However, for an audience of non-experts in health economic 
modeling, these analyses require careful interpretation and 
explanation, as they can easily be misunderstood. The use of 
PSA is, in our view, more problematic in case there is not yet 
any evidence of effectiveness of the technology, which was the 
case for most of the technologies that were included in our 
study. They were not yet used in clinical practice, not even in 
pilot settings. 
Several authors provide valuable suggestions for dealing 
with the lack of evidence in the early stages of development 
of a medical technology, such as clinical trial simulation and 
expert elicitation.2,6 Most of these focus on quantifying the 
known unknowns, with a focus on prediction. While in these 
cases PSA and value of information are technically possible, 
we argue that in such early stages exploration may be more 
valuable than prediction. For example, the use of expert 
elicitation may result in pseudo certainty if experts do not 
believe the innovation to be effective. Does this mean that we 
are certain that the innovation is not effective, or not cost-
effective, and that there is no value in performing further 
research? Whether explorative or predictive analyses are 
more valuable may also depend on the public, and the aim of 
the assessment. For a technology developer, it may be more 
informative to learn under what circumstances the technology 
will be cost-effective, than learning how likely it is that the 
technology will be cost-effective. 
In other fields of research, exploratory modeling is an 
important tool, which might be very useful in early health 
economic modeling, too. Exploratory modeling aims 
at providing decision support “even in the face of many 
irreducible uncertainties, by systematically exploring the 
consequences of a plethora of uncertainties – ranging from 
parametric uncertainties (eg, parameters ranges), over 
structural uncertainties (eg, different structures and models), 
to method uncertainties (eg, different modeling methods) 
– using computational models as scenario generators.”10 It 
stems from scenario thinking, but instead of calculating a 
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pre-determined set of scenarios, in exploratory modeling 
a comprehensive set of all possible scenarios that can be 
envisaged is simulated. It might be viewed as an n-way 
sensitivity analysis, where n includes all uncertain parameters 
at all possible (instead of probable) values. Then, the researcher 
can analyze under which circumstances a technology or 
strategy is disputable (eg, not cost-effective), and under which 
circumstances it is most valuable. Thus, exploratory modeling 
involves searching through the set of outcomes using (many-
objective) optimization algorithms.11 This also provides 
important information on what evidence should be collected, 
and what (adaptive) approach should be taken, for example in 
terms of coverage with evidence development. Kim et al refer 
to the use of early health economic modeling in ipilimumab 
for advanced melanoma in Australia.3 In the Netherlands, 
conditional reimbursement schemes with evidence collection 
are hardly based on uncertainties other than imprecision.12 
With use of exploratory modeling, one could explore under 
which circumstances (eg, at which survival rate, or in case 
of which parallel developments in the control of the relevant 
disease condition) ipilimumab is cost-effective. An adaptive 
strategy can then be implemented where evidence is collected 
and clear thresholds are set: if a certain threshold (eg, survival 
rate) is reached, reimbursement of the drug can be continued, 
if not, reimbursement should be withdrawn. With such an 
exploratory approach, we completely agree with Kim et al 
that “early health economic modelling could bridge this gap 
by better conceptualising the risks and uncertainties for both 
payers and sponsors.”3 This does, however, require a broader 
notion of uncertainty than imprecision.13,14
The Notion of Value
Many of the commentaries rightfully discussed our strong 
focus on cost-effectiveness. Of course, as we mentioned in 
the original paper, value of an innovative technology is much 
more than cost-effectiveness alone. We fully agree that “cost-
effectiveness alone may be too reductive if taken as the only 
decision rule, and it would benefit from being used within a 
broader evaluation framework.”2 Let us clarify that this mainly 
resulted from the focus of the paper, which was to study 
whether early health economic modeling could distinguish 
‘valuable’ from ‘non-valuable’ innovations.
In the underlying assessments we did not restrict our 
early analyses to economic modeling, but we did focus on 
the health economic part in this study. In the underlying 
advisory reports that were shared with the commissioners 
after the assessment, we did – qualitatively – include other 
aspects that might impact overall value, as we mentioned 
in the discussion section of our paper. Our assessments 
were technology-driven, which means that we assessed the 
technology and not the problem that the technology aimed 
to solve. We fully agree with Lehoux and Silva when they 
state that it is important to raise questions about the kinds of 
health innovations our systems of innovation should deliver.4 
Otherwise, as a society we risk developing brilliant solutions 
for non-existing or relatively marginal problems.15 But also 
when an assessment is technology-driven, it is important 
to explore, already in the earliest stages of development, 
whether the intended innovation is deemed valuable and 
relevant by different stakeholders, and what possible barriers 
and facilitators could be for its use. As Teljeur and Ryan state, 
“giving them consideration at an early stage may provide an 
opportunity to tackle any issues that might otherwise only 
become apparent at a late stage of product development and 
hamper reimbursement and or uptake.”7 
The Iterative Nature of Health Economic Modelling
Our analysis was based on 32 assessments of 30 unique 
innovations. This means that while for two innovations 
we performed two consecutive assessments at different 
time points, the others were single assessments. We agree 
with Drummond that ideally “early stage health economic 
modeling is not a ‘one-time’ activity, but should be continuous 
and iterative, with the modeling being updated as more 
information becomes available, either about the technology 
itself or the environment in which it would be used.”1,16 This 
relates to the exploratory modeling and adaptive approach 
mentioned before, where new pieces of evidence can be 
integrated in the model and may warrant a change of strategy. 
Then indeed “the more relevant decision focus may be a ‘not 
yet’ or ‘yes, but (with conditions)’ decision, using economic 
modelling as an iterative and ongoing process.”6 
We agree with Partington and Karnon that ideally such 
an iterative approach should include participatory methods 
that enable nuanced deliberation between stakeholders.6 
A participatory approach to modeling could enhance the 
confidence stakeholders have in models, their relevance 
to the decision-makers and their account of uncertainty.17 
Also, it would facilitate the broader notion of value as 
described in the previous paragraph, because stakeholders 
can deliberate on the value of the technology. To enable the 
iterative use of health economic models, not for just one 
technology but for different technologies aimed at a specific 
care pathway, Zawadzki and Hay suggest to make health 
economic models publicly available, “ideally in a standardized 
format to ensure consistent and complete representation of 
features, code, data sources, results, validation exercises, and 
policy recommendations.”8 This would indeed make health 
economic modeling more efficient, more transparent and will 
probably increase the quality of model-based assessments.18 
However, it should be noted that the 32 assessments in our 
database were almost all commissioned by the developer of 
the technology, often a medtech company. Making the models 
and accompanying documentation publicly available may be 
in conflict with the confidentiality that is generally required 
in such early stages.
Concluding Remarks
The commentaries seem to imply renewed interest in 
applying and further advancing the methodology of early 
health economic modeling. Our data were based on the first 
32 assessments, and may capture an evolving process and 
learning curve that may not be representative of a steady state 
process.7 We therefore strongly encourage others to share their 
results, so that we can learn from each other and improve our 
assessments. 
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While it is informative for developers, early health economic 
modeling has the ability to have broader value, in bringing 
together the views of different stakeholders, and bridging the 
gap from the first idea to patient access. Ideally, it is an iterative 
and ongoing process, guiding the development, research and 
implementation of innovations to maximize its value for 
society. To achieve such as role, we do agree with Lehoux and 
Silva that we need to “transform our scholarly traditions.”4 In 
our opinion this is not restricted to broadening our notion 
of value, but also includes for example our definition and 
assessment of uncertainty. In this, early health economic 
modeling can learn from other disciplines that provide 
decision support. However, when transforming traditions and 
methodology, we always need to ensure that the assessments 
match the needs of the decision-makers they inform. We 
believe that iterative, participatory and exploratory modeling 
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